Corona Remedies Ltd
Corona Remedies Ltd Live Price Chart
Performance
| Previous Close | ₹ 2050.3 |
| High | ₹ 2061.1 |
| Volume | 9583 |
| 52W Range | ₹ - ₹ |
| Open | ₹ 2060 |
| Low | ₹ 2021 |
| Market Cap | ₹ 12929.85 Cr |
Corona Remedies Ltd Technicals
| 20 Day | ₹ 2,097.500 |
| 50 Day | ₹ 2,032.217 |
| 100 Day | ₹ 1,906.759 |
| 200 Day | ₹ 1,716.924 |
| 20 Day | ₹ 2,108.627 |
| 50 Day | ₹ 2,058.104 |
| 100 Day | ₹ 1,878.453 |
| 200 Day | ₹ 1,531.556 |
Corona Remedies Ltd Fundamentals
| ROCE | 27.132 |
| P/E Ratio | 63.090 |
| P/B Ratio | 16.790 |
| Industry P/E | 16.790 |
| Debt to Equity | 51.376 |
| ROE | 24.780 |
| EPS | 32.460 |
| Dividend Yield | 0.490 |
| Book Value | 121.970 |
| Face Value | 10.000 |
Corona Remedies Ltd Financials
| Particulars | Y202603 | Y202503 | Y202403 | Y202303 | Y202203 |
|---|---|---|---|---|---|
| Total Revenue | 1413.83 | 1202.35 | 1020.9314 | 891.1014 | 623.9292 |
| Total Expenses | 1154.58 | 1004.2 | 902.4559 | 780.4404 | 624.7232 |
| Profit After Tax | 184.85 | 149.05 | 90.4975 | 84.7032 | -0.3993 |
Corona Remedies Ltd Shareholding Pattern
| Promoter Holdings | 68.996 % |
| FIIs | 3.629 % |
| DIIs | 0.397 % |
| MutualFund | 12.502 % |
| Retail | 0.893 % |
| Others - | 13.583 % |
About Corona Remedies Ltd
Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'. A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat). The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005. The production of first manufacturing plant was commissioned at Solan, Himachal Pradesh in 2007. The Company launched Gynaecology division in 2008; further launched Cardioloy division in 2013; launched Cardiovascular disease (CVD) and Solis division in 2016. Later, the production at Ahmedabad Plant commissioned in Gujarat in 2021. Radiance and Solaris Divisions launched in 2022; followed by Urology division in 2023. The Company acquired the Myoril brand from Sanofi Healthcare India Private Limited in strengthening the pain management portfolio in 2024. ...
Similar Stocks
| Ambalal Sarabhai Enterprises Ltd Pharmaceuticals | ₹ 43.92 -1.7 (-3.73%) |
| Amrutanjan Health Care Ltd Pharmaceuticals | ₹ 498.35 -11 (-2.16%) |
| Astrazeneca Pharma India Ltd Pharmaceuticals | ₹ 6,917.00 -34.5 (-0.5%) |
| Bliss GVS Pharma Ltd Pharmaceuticals | ₹ 630.40 +13.65 (+2.21%) |
| Abbott India Ltd Pharmaceuticals | ₹ 26,135.00 +285 (+1.1%) |
| Cipla Ltd Pharmaceuticals | ₹ 1,423.00 +13.8 (+0.98%) |
FAQs on Corona Remedies Ltd
1. Can I buy Corona Remedies Ltd from PL Capital? ›
2. Does Corona Remedies Ltd pay dividends? ›
3. What is the current share price of Corona Remedies Ltd ? ›
4. What is the 52-week high and low of Corona Remedies Ltd ? ›
Start SIP in Corona Remedies Ltd
Invest systematically in stocks with the
PL Capital app
Are you a new user? Open your account
